
Abstract

The present invention is directed to a compound represented by formula (1):



(1)

(wherein R^1 represents an alkyl group which may have a substituent or an alkenyl group which may have a substituent; and

each of R^2 and R^3 represents a hydrogen atom, an alkyl group, a hydroxyalkyl group, a dihydroxyalkyl group, or an alkynyl group, or R^2 and R^3 form, together with the nitrogen atom adjacent thereto, a nitrogen-containing saturated heterocyclic group which may have a substituent)
and a drug composition containing the compound. The compound exhibits tumor necrosis factor (TNF-α) production inhibitory effect and improved absorption upon oral administration.